Satellos Bioscience (NASDAQ:MSLE) Posts Earnings Results, Misses Expectations By $0.09 EPS

Satellos Bioscience (NASDAQ:MSLE) issued its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09), Zacks reports.

Satellos Bioscience Stock Performance

Shares of MSLE stock traded down $0.08 during trading hours on Friday, reaching $6.75. The company had a trading volume of 31,200 shares, compared to its average volume of 56,084. The stock has a fifty day moving average of $7.82 and a 200-day moving average of $8.20. The company has a market capitalization of $143.15 million, a price-to-earnings ratio of -3.51 and a beta of 1.63. Satellos Bioscience has a 12-month low of $5.30 and a 12-month high of $13.39.

Analysts Set New Price Targets

Several research firms recently commented on MSLE. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Satellos Bioscience in a research note on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Wednesday, November 4th. Craig Hallum assumed coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They set a “buy” rating and a $24.00 target price on the stock. Finally, Zacks Research lowered shares of Satellos Bioscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 21st. Six investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.60.

Satellos Bioscience Company Profile

Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.